Monte Rosa Therapeutics, Inc. (GLUE)
Designs drugs that make the body destroy disease-causing proteins naturally.
$22.04-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+360.1%
The outlook
GLUE trades at $22.04 and sits well above both its 50- and 200-day moving averages, reflecting upward momentum in its recent trend. Analyst consensus is strongly positive, with an average rating of Strong Buy and a price target implying significant upside relative to the current level. The stock is positioned near the upper end of its 52-week range.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 6 analysts
Price trendAbove its 50- & 200-day averages
52-week range83% of the way from its 52-week low to high
Price targetAvg target +58% vs current price
Analyst price target
~12-month · 6 analysts$34.83average target+58.0% vs now
Now $22.04
Low $29.00High $40.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.86B
52-wk high
$25.77
52-wk low
$4.12
50-day avg
$20.57
200-day avg
$17.93
Trailing P/E
—